Literature DB >> 29617753

An Examination of Appetite and Disordered Eating in Active Crohn's Disease.

Richard Anthony Wardle1, Gita Thapaliya1, Adam Nowak1, Shellie Radford1, Michelle Dalton2, Graham Finlayson3, Gordon W Moran1.   

Abstract

BACKGROUND: Crohn's disease [CD] patients suffer from nutritional deficiencies when in active disease. We aim to examine calorific intake, macronutrient choice, and disordered eating behaviour in patients with active CD.
METHODS: CD patients with matched healthy volunteers [HV] were recruited. Active disease was defined by faecal calprotectin >250 µg/g, C-reactive protein 83.8 ± 47.1 mg/dL, or active disease seen on endoscopy or imaging. Symptoms were quantified by Harvey‑Bradshaw Index [HBI]. Calorific intake was assessed by 24-h dietary recall. Disordered eating was assessed using validated questionnaires: Binge Eating Scale [BES]; Power of Food Scale [PFS]; Control of Eating Questionnaire [CoEQ]; Dutch Eating Behaviour Questionnaire [DEBQ]; and Three Factor Eating Questionnaire [TFEQ].
RESULTS: Totals of 30 CD (18 male[M]:12 female [F], age 32.3 ± 2.19 years, body mass index [BMI] 24.9 ± 0.8) and 31 matched HV [19 M:12 F, age 32.8 ± 2.0 years, BMI 24.7 ± 0.5] were recruited. Mean faecal calprotectin was 1032.5 ± 176 µg/g, C-reactive protein 8.38 ± 4.71 mg/dL, and HBI 4.8 ± 1. There were no significant differences in calorific intake between groups. Protein intake was lower in the CD cohort [p = 0.03]. Hospital Anxiety and Depression score was higher [p = 0.01] and CoEQ-Positive Mood [p = 0.001] lower in CD. CD patients were characterised by higher BES [p = 0.01] and lower CoEQ Craving Control [p = 0.027], with greater craving for Sweet [p = 0.043] and Savoury [p = 0.021] foods. PFS food Present [p = 0.005], DEBQ Emotional [p =< 0.001], and External Eating [p = 0.022] were significantly higher than among HV.
CONCLUSIONS: Reduced protein consumption and more prevalent disordered eating behaviour traits were present in CD. Greater binge eating and decreased control of cravings may be attributed to lower mood and higher anxiety observed. Patients may benefit from stronger psychological support with firm dietetic advice for healthy eating.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29617753     DOI: 10.1093/ecco-jcc/jjy041

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  6 in total

Review 1.  Growth Delay in Inflammatory Bowel Diseases: Significance, Causes, and Management.

Authors:  Kerry Wong; Daniela Migliarese Isaac; Eytan Wine
Journal:  Dig Dis Sci       Date:  2021-01-12       Impact factor: 3.199

2.  Dietary beliefs and recommendations in inflammatory bowel disease: a national survey of healthcare professionals in the UK.

Authors:  Benjamin Crooks; John McLaughlin; Jimmy Limdi
Journal:  Frontline Gastroenterol       Date:  2020-12-22

3.  Abdominal Pain and Anxious or Depressed State Are Independently Associated With Weight Loss in Inflammatory Bowel Disease.

Authors:  Venkata Subhash Gorrepati; Christopher Soriano; Ansh Johri; Shannon Dalessio; August Stuart; Walter Koltun; Andrew Tinsley; Kofi Clarke; Emmanuelle Williams; Matthew Coates
Journal:  Crohns Colitis 360       Date:  2020-06-03

4.  Body Mass Index and Disease Activity Are Associated With Moderate to Severe Disability in Crohn's Disease: A Cross-Sectional Study in Shanghai.

Authors:  DongSheng Bian; Yongmei Jiang; Yubei Gu; Zirui He; Qi Chen; Yonghua Tang; Jie Zhong; Yongmei Shi
Journal:  Front Med (Lausanne)       Date:  2021-07-09

5.  Practical Guidance for Dietary Management of Patients With Inflammatory Bowel Disease During the SARS-CoV2 Pandemic.

Authors:  Alice S Day; Jessica A Wood; Emma P Halmos; Robert V Bryant
Journal:  J Acad Nutr Diet       Date:  2020-07-20       Impact factor: 4.910

Review 6.  The Gut-Brain Axis and Its Role in Controlling Eating Behavior in Intestinal Inflammation.

Authors:  Gordon William Moran; Gita Thapaliya
Journal:  Nutrients       Date:  2021-03-18       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.